Esthesioneuroblastoma other imaging findings

Esthesioneuroblastoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Esthesioneuroblastoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Esthesioneuroblastoma other imaging findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Esthesioneuroblastoma other imaging findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Esthesioneuroblastoma other imaging findings
CDC on Esthesioneuroblastoma other imaging findings
Esthesioneuroblastoma other imaging findings in the news
Blogs on Esthesioneuroblastoma other imaging findings
Directions to Hospitals Treating Esthesioneuroblastoma
Risk calculators and risk factors for Esthesioneuroblastoma other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: {{Simrat}]

Other Imaging Findings

Other imaging studies for esthesioneuroblastoma include angiography/digital subtraction angiography and nuclear medicine.

Angiography/Digital subtraction angiography (DSA)

Angiography demonstrates a prominent tumour blush with arteriovenous shunting, and persistent opacification.

Nuclear Medicine

As with other neuroblastomas, olfactory neuroblastomas are -meta-iodobenzylguanidine, MIBG avid. This potentially helps to differentiate them from other tumors that arise in the region.